Implantation of the Micra transcatheter pacing system: Single Polish center experience with the real costs of hospitalization analysis.


Journal

Cardiology journal
ISSN: 1898-018X
Titre abrégé: Cardiol J
Pays: Poland
ID NLM: 101392712

Informations de publication

Date de publication:
2020
Historique:
received: 22 04 2018
accepted: 12 07 2018
revised: 12 07 2018
pubmed: 30 8 2018
medline: 8 6 2021
entrez: 30 8 2018
Statut: ppublish

Résumé

The Micra transcatheter pacing system (TPS) is a miniaturized, single-chamber pacemaker system. Study reported herein is an initial experience with implantation of the Micra TPS. The leadless pacemaker was implanted in 10 patients with standard indications for a permanent pacemaker implantation. All hospitalization costs were calculated for all patients. The mean age of the patients was 75 ± 7.1 years, 6 were men and 4 were women. Four patients had permanent atrial fibrillation as the basal rhythm and 6 patients had sinus rhythm. All patients had at least one relative contraindication that precluded the use of a traditional pacing system. Mean intraoperative ventricular sensing amplitude was 10.6 ± 5.4 mV, impedance 843 ± 185 ohms, and pacing threshold at 0.24 ms was 0.56 ± 0.23 V. At discharge, those values were 13.9 ± 5.6 mV, 667 ± 119 ohms and 0.47 ± 0.17, respectively. The mean duration of implantation procedure was 82 min, while mean fluoroscopy time was 3.5 min. Two patients developed hematoma at the groin puncture site post-implantation. In 1 case there was a need for erythrocyte mass transfusion and surgical intervention. Mean total time of hospitalization was 26 days and time from procedure to discharge 12 days. Average cost of hospitalization per 1 patient was 11,260.15 EUR minimal cost was 9,052.68 EUR, while maximal cost was 16,533.18 EUR. Implantation of leadless pacemakers is feasible, safe and provides advantages over the conventional system. Hospitalization costs vary for individual patients in wide range.

Sections du résumé

BACKGROUND
The Micra transcatheter pacing system (TPS) is a miniaturized, single-chamber pacemaker system. Study reported herein is an initial experience with implantation of the Micra TPS.
METHODS
The leadless pacemaker was implanted in 10 patients with standard indications for a permanent pacemaker implantation. All hospitalization costs were calculated for all patients.
RESULTS
The mean age of the patients was 75 ± 7.1 years, 6 were men and 4 were women. Four patients had permanent atrial fibrillation as the basal rhythm and 6 patients had sinus rhythm. All patients had at least one relative contraindication that precluded the use of a traditional pacing system. Mean intraoperative ventricular sensing amplitude was 10.6 ± 5.4 mV, impedance 843 ± 185 ohms, and pacing threshold at 0.24 ms was 0.56 ± 0.23 V. At discharge, those values were 13.9 ± 5.6 mV, 667 ± 119 ohms and 0.47 ± 0.17, respectively. The mean duration of implantation procedure was 82 min, while mean fluoroscopy time was 3.5 min. Two patients developed hematoma at the groin puncture site post-implantation. In 1 case there was a need for erythrocyte mass transfusion and surgical intervention. Mean total time of hospitalization was 26 days and time from procedure to discharge 12 days. Average cost of hospitalization per 1 patient was 11,260.15 EUR minimal cost was 9,052.68 EUR, while maximal cost was 16,533.18 EUR.
CONCLUSIONS
Implantation of leadless pacemakers is feasible, safe and provides advantages over the conventional system. Hospitalization costs vary for individual patients in wide range.

Identifiants

pubmed: 30155871
pii: VM/OJS/J/58112
doi: 10.5603/CJ.a2018.0075
pmc: PMC8086506
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

47-53

Références

Circulation. 2010 Jan 26;121(3):458-77
pubmed: 20048212
J Cardiovasc Electrophysiol. 2016 Sep;27(9):1067-71
pubmed: 27296508
N Engl J Med. 2016 Feb 11;374(6):533-41
pubmed: 26551877
Heart Rhythm. 2017 Sep;14(9):1375-1379
pubmed: 28502871
J Am Coll Cardiol. 2007 May 8;49(18):1851-9
pubmed: 17481444
Heart Rhythm. 2012 May;9(5):728-35
pubmed: 22182495
Eur Heart J. 2015 Oct 1;36(37):2510-9
pubmed: 26045305
N Engl J Med. 2015 Sep 17;373(12):1125-35
pubmed: 26321198
J Cardiovasc Electrophysiol. 2016 Dec;27(12):1495-1501
pubmed: 27600684
J Am Coll Cardiol. 2015 Apr 21;65(15):1497-504
pubmed: 25881930
Eur Heart J. 2014 May;35(18):1186-94
pubmed: 24347317
Heart Rhythm. 2017 May;14(5):702-709
pubmed: 28192207

Auteurs

Marcin Grabowski (M)

1st Department of Cardiology, Medical University of Warsaw, Poland. marcin.grabowski@wum.edu.pl.

Marcin Michalak (M)

1st Department of Cardiology, Medical University of Warsaw, Poland.

Monika Gawałko (M)

1st Department of Cardiology, Medical University of Warsaw, Poland.

Sylwia Gajda (S)

1st Department of Cardiology, Medical University of Warsaw, Poland.

Andrzej Cacko (A)

1st Department of Cardiology, Medical University of Warsaw, Poland.

Łukasz Januszkiewicz (Ł)

1st Department of Cardiology, Medical University of Warsaw, Poland.

Agnieszka Kołodzińska (A)

1st Department of Cardiology, Medical University of Warsaw, Poland.

Przmysław P Mitkowski (PP)

Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland.

Gabor Z Duray (GZ)

Clinical Electrophysiology Department of Cardiology, Medical Center, Hungarian Defence Forces, Budapest, Hungary.

Grzegorz Opolski (G)

1st Department of Cardiology, Medical University of Warsaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH